https://taurx.com/media/taurx-welcomes-summit-with-uks-top-patient-advocacy-groups2026-07-09T05:54:57-07:00weekly0.5https://taurx.com/media/journal-of-prevention-of-alzheimers-disease-publishes-results-from-confirmatory-taurx-study-into-efficacy-of-potential-oral-treatment2026-05-18T00:49:59-07:00weekly0.5https://taurx.com/media/taurx-donates-2-500-to-baby-loss-charity-sands2026-05-18T00:52:34-07:00weekly0.5https://taurx.com/media/journal-of-prevention-of-alzheimers-disease-publishes-trial-results-showing-hmtm-potentially-offers-accessible-oral-treatment-option-for-patients-with-early-alzheimers-disease2026-06-01T07:54:41-07:00weekly0.5https://taurx.com/media/taurx-submits-uk-marketing-authorisation-application-for-hmtm-as-a-treatment-for-alzheimers-disease2026-06-02T02:06:52-07:00weekly0.5https://taurx.com/media/two-year-sustained-cognitive-benefits-of-hydromethylthionine-mesylate-hmtm-indicated-by-taurxs-lucidity-trial2026-06-01T08:04:25-07:00weekly0.5https://taurx.com/media/taurx-to-present-two-year-data-from-phase-iii-trial-of-hmtm-in-alzheimers-disease-at-the-ad-pd-2024-conference-in-march2026-06-01T08:09:48-07:00weekly0.5https://taurx.com/media/taurxs-hydromethylthionine-mesylate-hmtm-demonstrates-significant-reduction-in-neurodegeneration-in-alzheimers-disease-ad-22026-06-02T02:18:37-07:00weekly0.5https://taurx.com/media/taurxs-hydromethylthionine-mesylate-hmtm-demonstrates-significant-reduction-in-neurodegeneration-in-alzheimers-disease-ad2026-06-01T08:13:37-07:00weekly0.5https://taurx.com/media/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm-the-only-oral-anti-tau-therapy-in-late-stage-development2026-06-01T08:21:13-07:00weekly0.5https://taurx.com/media/taurx-announces-additional-investment-of-usd119-million-following-announcement-of-phase-3-lucidity-topline-results2026-06-04T08:09:26-07:00weekly0.5https://taurx.com/media/taurx-welcomes-new-chief-medical-officer-dr-richard-stefanacci2026-06-01T08:27:09-07:00weekly0.5https://taurx.com/media/taurx-pharmaceuticals-organises-information-meeting-for-alzheimer-europe-members2026-06-01T08:30:44-07:00weekly0.5https://taurx.com/media/initial-data-of-lucidity-study2026-06-01T08:35:31-07:00weekly0.5https://taurx.com/media/taurx-announce-lucidity-trial-fully-randomised2026-07-20T03:34:47-07:00weekly0.5https://taurx.com/media/taurx-completes-enrolment-of-phase-iii-trial-and-reveals-positive-new-analyses2026-06-01T08:53:57-07:00weekly0.5https://taurx.com/media/new-scientific-illustrations-to-explain-the-role-of-tau-proteins-in-alzheimers-disease2026-06-02T02:02:55-07:00weekly0.5https://taurx.com/media/preclinical-study-shows-how-commonly-prescribed-drugs-for-alzheimers-disease-interfere-with-the-activity-of-the-tau-aggregation-inhibitor-hydromethylthionine2026-06-02T01:58:45-07:00weekly0.5https://taurx.com/media/new-study-shows-a-minimum-dose-of-hydromethylthionine-could-slow-cognitive-decline-and-brain-atrophy-in-mild-to-moderate-alzheimers-disease2026-05-18T00:59:07-07:00weekly0.5https://taurx.com/media/taurx-recognized-as-a-technology-innovation-leader-in-the-neurodegenerative-disease-management-industry2026-05-18T01:01:03-07:00weekly0.5https://taurx.com/media/fda-grants-orphan-drug-designation-for-taurxs-lmtx-in-frontotemporal-dementia2026-05-18T01:04:28-07:00weekly0.5https://taurx.com/media/lucidity-study-protocol-amendment2026-05-18T01:05:59-07:00weekly0.5https://taurx.com/media/alzheimer-candidate-lmtx-inhibits-α-sync-aggregation-in-pre-clinical-parkinsons-disease-study-published-in-the-frontiers-in-molecular-neuroscience2026-05-18T01:08:12-07:00weekly0.5https://taurx.com/media/second-phase-3-study-results-for-lmtx-published-in-the-journal-of-alzheimers-disease2026-05-18T01:09:54-07:00weekly0.5https://taurx.com/media/topline-results-from-taurx-therapeutics-ltd-s-second-phase-3-study-in-alzheimers-disease-presented-at-ctad2026-07-20T06:32:03-07:00weekly0.5https://taurx.com/media/trx-237-015-phase-3-clinical-trial-in-alzheimers-disease-full-study-results-published-in-the-lancet2026-07-20T06:30:26-07:00weekly0.5https://taurx.com/media/trx-237-007-phase-3-clinical-trial-fails-to-achieve-its-coprimary-endpoints2026-05-18T01:15:13-07:00weekly0.5https://taurx.com/media/taurx-reports-first-phase-3-results-for-lmtx-promising-read-out-for-first-ever-tau-aggregation-inhibitor-to-enter-phase-3-trials2026-05-18T01:16:48-07:00weekly0.5https://taurx.com/media/taurx-completes-lmtx-phase-iii-clinical-trial2026-05-18T01:18:16-07:00weekly0.5https://taurx.com/media/taurx-adds-to-growing-body-of-evidence-supporting-tau-aggregation-inhibition-with-publication-of-six-new-journal-articles2026-05-18T01:19:43-07:00weekly0.5https://taurx.com/media/first-evidence-of-potential-efficacy-of-tau-aggregation-inhibitor-therapy-in-alzheimers-disease-taurx-publishes-positive-results-of-phase-ii-clinical-trial-in-the-journal-of-alzheimers-disease2026-05-18T01:22:23-07:00weekly0.5